A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties <i>in vivo</i>.

Oncotarget · 2020 · PMC7566808 · PMID 33110477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Importantly, there was a decreasing trend of CD4 + FoxP3 + in the tumors of mice treated with L19L19-IL2 with anti-PD-1 ( Figure 5 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.